Presentations

Presentations

Presentations

Date	Title	Format/Plug-in Support
October 31, 2024	CTAD 2024_Pepinemab for VCNX Presentation	CTAD 2024_Pepinemab for VCNX Presentation 2.9 MB
September 10, 2024	CRI-ENCI Eighth International Cancer Immunotherapy Conference (CICON): Translating Science into Survival Presentation	CRI-ENCI Eighth International Cancer Immunotherapy Conference (CICON): Translating Science into Survival Presentation 1.1 MB
July 31, 2024	Alzheimer's Association International Conference® (AAIC) Presentation	Alzheimer's Association International Conference® (AAIC) Presentation 1.6 MB
June 1, 2024	ASCO Conference Presentation	ASCO Conference Presentation 1.9 MB
April 25, 2024	12th Alzheimer’s & Parkinson’s Drug Development Summit Presentation	12th Alzheimer’s & Parkinson’s Drug Development Summit Presentation 3.2 MB
April 16, 2024	Festival of Biologics Presentation	Festival of Biologics Presentation 1.6 MB
October 26, 2023	Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease: clinical proof of concept in Phase 2 HD study supports clinical development in and ongoing Phase 1/2 AD study	Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease: clinical proof of concept in Phase 2 HD study supports clinical development in and ongoing Phase 1/2 AD study 3.1 MB
October 4, 2023	Keystone Symposium: B cells and TLS_POSTER	Keystone Symposium: B cells and TLS_POSTER 2.6 MB
September 27, 2023	AACR SPECIAL CONFERENCE IN CANCER RESEARCH: PANCREATIC CANCER	AACR SPECIAL CONFERENCE IN CANCER RESEARCH: PANCREATIC CANCER 1.6 MB
September 26, 2023	DOT2023poster	DOT2023poster 1.8 MB
August 30, 2023	DOT2023presentation	DOT2023presentation 5.6 MB
June 5, 2023	ASCO Poster - PDAC study abstract # TPS4195	ASCO Poster - PDAC study abstract # TPS4195 2.3 MB
May 15, 2023	PEGS Boston 2023. Native complex membrane antigen expression on poxvirus for antibody discovery	PEGS Boston 2023. Native complex membrane antigen expression on poxvirus for antibody discovery 2.1 MB
April 26, 2023	Corporate Presentation	Corporate Presentation 4.7 MB
January 10, 2023	Corporate Presentation	Corporate Presentation 4.2 MB
November 11, 2022	Neoadjuvant SEMA4D blockade with nivolumab alters suppressive myeloid cells while elevating B cell and CD26hi T cell infiltration in the tumors of patients with resectable stage III melanoma	Neoadjuvant SEMA4D blockade with nivolumab alters suppressive myeloid cells while elevating B cell and CD26hi T cell infiltration in the tumors of patients with resectable stage III melanoma 8.1 MB
November 10, 2022	Phase I Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab/Trastuzumab in Patients with Metastatic HER2-Positive Breast Cancer (MBC)	Phase I Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab/Trastuzumab in Patients with Metastatic HER2-Positive Breast Cancer (MBC) 3 MB
November 4, 2022	HSG Highlight: SIGNAL Trial Results	HSG Highlight: SIGNAL Trial Results 2.7 MB
September 16, 2022	Synthesis of key results and conclusions of the SIGNAL phase 2 study of pepinemab as a treatment for early HD	Synthesis of key results and conclusions of the SIGNAL phase 2 study of pepinemab as a treatment for early HD 2.7 MB
September 13, 2022	Neoadjuvant Pepinemab in Combination with Nivolumab and/or Ipilimumab in Resectable Stage III Melanoma	Neoadjuvant Pepinemab in Combination with Nivolumab and/or Ipilimumab in Resectable Stage III Melanoma 1.1 MB
July 31, 2022	Corporate Presentation	Corporate Presentation 3.4 MB
June 10, 2022	Corporate Presentation	Corporate Presentation 3.4 MB
May 2, 2022	PEGS Boston 2022. Native complex membrane antigen expression on poxvirus for antibody discovery	PEGS Boston 2022. Native complex membrane antigen expression on poxvirus for an…
May 2, 2022	PEGS Boston 2022. Native complex membrane antigen expression on poxvirus for antibody discovery	PEGS Boston 2022. Native complex membrane antigen expression on poxvirus for antibody discovery 1.7 MB
April 27, 2022	Corporate Presentation	Corporate Presentation 6.8 MB
April 11, 2022	AACR Annual Meeting 2022 poster: Phase 1/2 study of pepinemab with pembrolizumab for first-line treatment of R/M Head and Neck Cancer	AACR Annual Meeting 2022 poster: Phase 1/2 study of pepinemab with pembrolizumab for first-line treatment of R/M Head and Neck Cancer 1.9 MB
April 11, 2022	AACR Annual Meeting 2022 poster: Phase 1/2 study of pepinemab with pembrolizumab for first-line treatment of R/M Head and Neck Cancer	AACR Annual Meeting 2022 poster: Phase 1/2 study of pepinemab with pembrolizuma…
April 2, 2022	American Academy of Neurology 2022 Annual Meeting Poster: Clinical evidence that treatment with pepinemab, a novel regulator of neuroinflammation, may provide cognitive benefit to patients with Huntington’s and potentially other neurodegenerative diseases	American Academy of Neurology 2022 Annual Meeting Poster: Clinical evidence that treatment with pepinemab, a novel regulator of neuroinflammation, may provide cognitive benefit to patients with Huntington’s and potentially other neurodegenerative diseases 2.2 MB
March 2, 2022	2022 CHDI poster: Combination anti-SEMA4D immunotherapy and HTT-lowering ASO provide benefit beyond either individual therapy in preclinical HD mouse model	2022 CHDI poster: Combination anti-SEMA4D immunotherapy and HTT-lowering ASO provide benefit beyond either individual therapy in preclinical HD mouse model 5.9 MB
February 24, 2022	2022 HNSCC Symposium Poster: Phase 1/2 study of pepinemab in combination with pembrolizumab as first-line treatment of advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84)	2022 HNSCC Symposium Poster: Phase 1/2 study of pepinemab in combination with pembrolizumab as first-line treatment of advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84) 1.6 MB
February 7, 2022	Corporate Presentation	Corporate Presentation 5.1 MB
January 5, 2022	Corporate Presentation	Corporate Presentation 4.6 MB
November 18, 2021	Corporate Presentation	Corporate Presentation 4 MB
November 12, 2021	SITC 2021 poster: Phase 1/2 study to evaluate pepinemab in combination with pembrolizumab in advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84)	SITC 2021 poster: Phase 1/2 study to evaluate pepinemab in combination with pembrolizumab in advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84) 10.7 MB
November 11, 2021	CTAD 2021 presentation: SEMA4D blocking antibody, pepinemab , is a novel potential treatment for neurodegenerative disease: clinical proof of concept in HD supports clinical development in AD	CTAD 2021 presentation: SEMA4D blocking antibody, pepinemab , is a novel potential treatment for neurodegenerative disease: clinical proof of concept in HD supports clinical development in AD 2.8 MB
November 5, 2021	HSG 2021: UNMASKING HD. The 28th Annual Meeting of the Huntington Study Group	HSG 2021: UNMASKING HD. The 28th Annual Meeting of the Huntington Study Group
November 5, 2021	Pepinemab – Anti-SEMA4D Antibody Treatment for Huntington’s Disease	Pepinemab – Anti-SEMA4D Antibody Treatment for Huntington’s Disease 2.3 MB
September 22, 2021	Corporate Presentation	Corporate Presentation 4.7 MB
September 10, 2021	EHDN2021 Annual Meeting_PLENARY III: SIGNAL results and lessons learnt	EHDN2021 Annual Meeting_PLENARY III: SIGNAL results and lessons learnt
August 11, 2021	Corporate Presentation	Corporate Presentation 4.8 MB
June 1, 2021	Corporate Presentation	Corporate Presentation 4.9 MB
April 29, 2021	16th Annual HD Therapeutics Conference Video Presentation	16th Annual HD Therapeutics Conference Video Presentation
April 29, 2021	Zauderer - Pepinemab SEMA4D Antibody: Potential Treatment for Neurodegenerative Disease	Zauderer - Pepinemab SEMA4D Antibody: Potential Treatment for Neurodegenerative Disease 958.2 KB
April 29, 2021	Poster - SEMA4D upregulation signals neuronal stress and triggers reactive astrogliosis	Poster - SEMA4D upregulation signals neuronal stress and triggers reactive astrogliosis 1.8 MB
April 29, 2021	Poster - Results of phase 2 SIGNAL trial of the SEMA4D blocking antibody	Poster - Results of phase 2 SIGNAL trial of the SEMA4D blocking antibody 1.3 MB
March 16, 2021	Corporate Presentation	Corporate Presentation 4.8 MB
March 9, 2021	AD/PD 2021 Presentation	AD/PD 2021 Presentation 2.2 MB
January 6, 2021	Corporate Presentation	Corporate Presentation 5.3 MB
November 18, 2020	Learnings from SIGNAL Phase 2 Study	Learnings from SIGNAL Phase 2 Study 2.4 MB
September 22, 2020	SIGNAL Huntington’s Disease Trial (VX15-2503-N-131): Cohort B Topline Results	SIGNAL Huntington’s Disease Trial (VX15-2503-N-131): Cohort B Topline Results 461.6 KB
July 29, 2020	Poster: Alzheimer's Association International Conference (AAIC) Evidence that semaphorin 4D is upregulated in neurons in Huntington’s and Alzheimer’s diseases, effects of anti-SEMA4D antibody on FDG PET in a HD clinical trial; rationale for its use in AD	Poster: Alzheimer's Association International Conference (AAIC) Evidence that semaphorin 4D is upregulated in neurons in Huntington’s and Alzheimer’s diseases, effects of anti-SEMA4D antibody on FDG PET in a HD clinical trial; rationale for its use in AD 4.7 MB
July 10, 2020	Corporate Presentation	Corporate Presentation 5.4 MB
July 1, 2020	Vaccinex Featured on Pharma’s Almanac	Vaccinex Featured on Pharma’s Almanac
June 29, 2020	Dr. Maurice Zauderer, President & CEO of Vaccinex, was interviewed by WuXi AppTec and featured on WuXi Press	Dr. Maurice Zauderer, President & CEO of Vaccinex, was interviewed by WuXi AppT…
June 26, 2020	Dr. Maurice Zauderer, President & CEO of Vaccinex, is interviewed on Rare Cast™ by Daniel Levine. “Treating Huntington's Disease by Addressing Neuroinflammation”	Dr. Maurice Zauderer, President & CEO of Vaccinex, is interviewed on Rare Cast™…
June 16, 2020	Replay of Maurice Zauderer, Ph.D., President and Chief Executive Officer of Vaccinex presenting at the Virtual Investor Fireside Chat Series	Replay of Maurice Zauderer, Ph.D., President and Chief Executive Officer of Vac…
May 29, 2020	ASCO Presentation: Abstract #3011 Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC.	ASCO Presentation: Abstract #3011 Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC. 1.4 MB
May 29, 2020	Detailed supporting data for ASCO Abstract #3011	Detailed supporting data for ASCO Abstract #3011 1.7 MB
April 27, 2020	Audio / Visual Presentation: Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Non-Small Cell Lung Cancer Presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting	Audio / Visual Presentation: Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Non-Small Cell Lung Cancer Presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting 13.3 MB
April 7, 2020	Virtual Presentation at the “Advances in Alzheimer’s and Parkinson’s Therapies AAT-AD/PD™ Focus Meeting 2020”	Virtual Presentation at the “Advances in Alzheimer’s and Parkinson’s Therapies AAT-AD/PD™ Focus Meeting 2020” 3.5 MB
February 27, 2020	Poster: 2020 Head and Neck Cancers Symposium. “Integrated Biomarker Study of Pepinemab in Combination With Ipilimumab or Nivolumab to Evaluate Immune Cell Composition of TME in Patients With Head And Neck Squamous Cell Carcinoma and Other Solid Tumors”	Poster: 2020 Head and Neck Cancers Symposium. “Integrated Biomarker Study of Pepinemab in Combination With Ipilimumab or Nivolumab to Evaluate Immune Cell Composition of TME in Patients With Head And Neck Squamous Cell Carcinoma and Other Solid Tumors” 2.3 MB
February 25, 2020	Poster: 2020 HD Therapeutics Conference Sponsored by CHDI. “Pepinemab, an anti-semaphorin 4D blocking antibody as a potential treatment for neurodegenerative disease: Treatment rationale and SIGNAL HD and AD trial updates.”	Poster: 2020 HD Therapeutics Conference Sponsored by CHDI. “Pepinemab, an anti-semaphorin 4D blocking antibody as a potential treatment for neurodegenerative disease: Treatment rationale and SIGNAL HD and AD trial updates.” 2.5 MB
February 14, 2020	Corporate Presentation	Corporate Presentation 4.7 MB
February 6, 2020	ASCO-SITC Clinical Immuno-Oncology Symposium SEMA4D-related Oral Presentation: Antibody Blockade of Semaphorin 4D Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade	ASCO-SITC Clinical Immuno-Oncology Symposium SEMA4D-related Oral Presentation: Antibody Blockade of Semaphorin 4D Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade 4.8 MB
February 6, 2020	ASCO-SITC Clinical Immuno-Oncology Symposium SEMA4D-related Oral Presentation: CLASSICAL-Lung Combination Trial of Pepinemab with Avelumab	ASCO-SITC Clinical Immuno-Oncology Symposium SEMA4D-related Oral Presentation: CLASSICAL-Lung Combination Trial of Pepinemab with Avelumab 2.9 MB
December 7, 2019	Oral Presentation: 2019 Clinical Trial on Alzheimer’s Disease (CTAD) Meeting: “Regulation of glial cell activation and neurodegeneration by anti-semaphorin 4D antibody pepinemab, a potential treatment for Alzheimer’s and Huntington’s Disease"	Oral Presentation: 2019 Clinical Trial on Alzheimer’s Disease (CTAD) Meeting: “Regulation of glial cell activation and neurodegeneration by anti-semaphorin 4D antibody pepinemab, a potential treatment for Alzheimer’s and Huntington’s Disease" 2.5 MB
November 9, 2019	Poster: Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). Updated interim results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC patients	Poster: Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). Updated interim results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC patients 2.4 MB
November 9, 2019	Poster: Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). SEMA4D antibody blockade overcomes mechanisms of immune suppression and combination immunotherapy including TGFβ blockade promotes efficient tumor regression	Poster: Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). SEMA4D antibody blockade overcomes mechanisms of immune suppression and combination immunotherapy including TGFβ blockade promotes efficient tumor regression 1.8 MB
September 27, 2019	Invited Podium Presentation: The Fifth International Cancer lmmunotherapy Conference in Paris, France Interim results from pepinemab in combination with avelumab in NSCLC patients who progressed on prior anti-PDx therapy (CLASSICAL – Lung)	Invited Podium Presentation: The Fifth International Cancer lmmunotherapy Conference in Paris, France Interim results from pepinemab in combination with avelumab in NSCLC patients who progressed on prior anti-PDx therapy (CLASSICAL – Lung) 4.2 MB
September 27, 2019	Poster: The Fifth International Cancer lmmunotherapy Conference in Paris, France Interim results from pepinemab in combination with avelumab in NSCLC patients who progressed on prior anti-PDx therapy (CLASSICAL – Lung)	Poster: The Fifth International Cancer lmmunotherapy Conference in Paris, France Interim results from pepinemab in combination with avelumab in NSCLC patients who progressed on prior anti-PDx therapy (CLASSICAL – Lung) 3.3 MB
September 24, 2019	Vaccinex Presentation at the Ladenburg Thalmann 2019 Healthcare Conference September 24, 2019	Vaccinex Presentation at the Ladenburg Thalmann 2019 Healthcare Conference September 24, 2019 5.1 MB
July 16, 2019	Poster Presented at the Alzheimer’s Association International Conference® (AAIC®): VX15 Anti-Semaphorin 4D Antibody (pepinemab) Increases FDG-PET Signal and is a Potential Treatment for Alzheimer’s Disease	Poster Presented at the Alzheimer’s Association International Conference® (AAIC®): VX15 Anti-Semaphorin 4D Antibody (pepinemab) Increases FDG-PET Signal and is a Potential Treatment for Alzheimer’s Disease 2 MB
June 18, 2019	Keystone Symposia - Neurodegenerative Diseases: New Insights and Therapeutic Opportunities Poster Title: “Blocking Semaphorin 4D to regulate glial cell activation and neurodegeneration – a potential treatment for Huntington’s Disease”	Keystone Symposia - Neurodegenerative Diseases: New Insights and Therapeutic Opportunities Poster Title: “Blocking Semaphorin 4D to regulate glial cell activation and neurodegeneration – a potential treatment for Huntington’s Disease” 2.9 MB
June 3, 2019	ASCO Annual Meeting Poster: Pilot Integrated Biomarker Study of VX15/2503 in Combination with Ipilimumab and/or Nivolumab in Patients with Resectable Metastatic Melanoma	ASCO Annual Meeting Poster: Pilot Integrated Biomarker Study of VX15/2503 in Combination with Ipilimumab and/or Nivolumab in Patients with Resectable Metastatic Melanoma 2 MB
June 1, 2019	ASCO Annual Meeting Poster: Preliminary Results From CLASSICAL-Lung, a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer (NSCLC)	ASCO Annual Meeting Poster: Preliminary Results From CLASSICAL-Lung, a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer (NSCLC) 2.1 MB
June 1, 2019	ASCO Annual Meeting Abstract: Preliminary Results From CLASSICAL-Lung, a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer (NSCLC)	ASCO Annual Meeting Abstract: Preliminary Results From CLASSICAL-Lung, a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer (NSCLC) 108.7 KB
April 29, 2019	Poster Presented on April 29, 2019 at AACR-AHNS Head and Neck Cancer Conference: “Integrated biomarker trials to evaluate myeloid and lymphoid composition of HNSCC and solid tumors treated with pepinemab and combinations with checkpoint inhibitors”	Poster Presented on April 29, 2019 at AACR-AHNS Head and Neck Cancer Conference: “Integrated biomarker trials to evaluate myeloid and lymphoid composition of HNSCC and solid tumors treated with pepinemab and combinations with checkpoint inhibitors” 2.7 MB
April 1, 2019	AACR 2019 Meeting: Interim results from CLASSICAL-Lung, a phase 1b/2 Study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC	AACR 2019 Meeting: Interim results from CLASSICAL-Lung, a phase 1b/2 Study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC 1.7 MB
April 1, 2019	AACR 2019 Meeting: Altered myeloid & lymphoid composition of tumor microenvironment following anti-SEMA4D and immunotherapies	AACR 2019 Meeting: Altered myeloid & lymphoid composition of tumor microenvironment following anti-SEMA4D and immunotherapies 2.3 MB
April 1, 2019	AACR 2019 Meeting: Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors	AACR 2019 Meeting: Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors 1.9 MB
January 18, 2019	PEPTALK: Advancing CNS Biotherapeutics and Crossing the Blood-Brain Barrier Presentation	PEPTALK: Advancing CNS Biotherapeutics and Crossing the Blood-Brain Barrier Presentation 3.7 MB
November 16, 2018	Podium Presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting	Podium Presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 4.8 MB
November 16, 2018	Presentation at the 2018 Huntington’s Study Group (HSG) Annual Meeting	Presentation at the 2018 Huntington’s Study Group (HSG) Annual Meeting 2.2 MB
November 16, 2018	Poster at the Society for Immunotherapy of Cancer (SITC) Annual Meeting	Poster at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 4.2 MB
October 4, 2018	Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Poster	Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Poster 2.3 MB
October 4, 2018	Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Presentation	Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Presentation 3.9 MB
SITC Presentation	SITC Presentation 2.4 MB